A single-compartment model cannot describe passive expiration in intubated, paralysed humans

…, JF Dhainaut, D Paccaly… - European …, 1991 - Eur Respiratory Soc
The time-course of thoracic volume changes (respiratory inductive plethysmograph) during
relaxed expiration was studied in 11 intubated, paralysed, mechanically ventilated subjects. …

Modelling of passive expiration in patients with adult respiratory distress syndrome

…, A Chelucci, A Allegra, D Paccaly… - European …, 1993 - Eur Respiratory Soc
The time-course of volume change during passive expiration preceded by an end-inspiratory
hold was studied with a biexponential model in six adult respiratory distress syndrome (…

Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler

…, S Newman, J Zhang, D Paccaly… - American journal of …, 2004 - journals.lww.com
A pharmacoscintigraphic study was conducted to compare the dose deposition of HMR 1031
from the existing nebulizer formulation and the new Ultrahaler device to help determine the …

Pharmacokinetic interactions between theophylline and rioprostil

…, E Rey, P Çathis, MO Richard, D Paccaly… - Scandinavian Journal …, 1989 - Taylor & Francis
The study is of double-blind crossover design. The effects of rioprostil, an analogue of
prostaglandin E, at a dose of 300 μg bd, and placebo on the kinetic of slow-release theophylline …

… ‐74: A model‐based approach for evaluating potential contamination of blood samples from a common indwelling catheter and its effects on estimated Actinomycin‐D …

DA Paccaly, JM Skolnik, PC Adamson… - Clinical …, 2006 - Wiley Online Library
INTRODUCTION A structural model derived from Actinomycin‐D (Act‐D) exposure following
dosing through a central venous line (CVL) and sampling from a peripheral vein was …

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

…, LJ Geiter, CD Wells, AJ Paccaly… - … of tuberculosis and …, 2011 - ingentaconnect.com
… tuberculosis sur des plaques d’agar à partir de prélèvements des crachats nocturnes pour
calculer l’activité bactéricide précoce (EBA) définie sous forme d’une chute du log10 cfu/ml de …

[HTML][HTML] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

…, R Passalacqua, S Li, K McGuire, M Kaul, A Paccaly… - Nature Medicine, 2022 - nature.com
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …

Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters

C Xu, A Rafique, T Potocky, A Paccaly… - The Journal of …, 2021 - Wiley Online Library
We evaluated interleukin‐6 (IL‐6) receptor‐α subunit (IL‐6Rα) signaling inhibition with
sarilumab and tocilizumab, the association between IL‐6Rα receptor occupancy (RO) and C‐…

[HTML][HTML] Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

F Yang, AJ Paccaly, RK Rippley, JD Davis… - … of Pharmacokinetics and …, 2021 - Springer
Cemiplimab, a human monoclonal antibody targeting programmed cell death-1 (PD-1)
receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety …

Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma

…, J Cohen, PJ Sterk, B Miller, A Paccaly… - American journal of …, 2007 - atsjournals.org
Rationale: The tachykinins substance P and neurokinin A (NKA) are implicated in the
pathophysiology of asthma. Objective: We tested the safety, tolerability, and pharmacologic and …